EGFR Mutations Lung Cancer | Medical Algorithm

Evaluation

Are you evaluating a patient with a lung adenocarcinoma?

Yes

Does the tumor show an EGFR mutation?

Yes

Does the EGFR mutation profile show a responsive type?

Yes

Does FISH show an EML4-ALK gene rearrangement?

Yes

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Is the patient a candidate for therapy with an EGFR TKI?

Is the patient a candidate for therapy with an AKI TKI?

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
- Risk Factors for Lung Cancer
Imaging Studies
- False-Positive & False-Negative Findings for Lung Cancer Associated with Positron Emission Tomography (PET)
Laboratory Tests
- Circulating Tumor Cells (CTC) in Patient with Lung Cancer
- Detection of EGFR Mutation in Non-Small Cell Lung Carcinoma Using Immunohistochemistry (IHC)
Other Testing
- Detection of EGFR Mutation in Non-Small Cell Lung Carcinoma Using Immunohistochemistry (IHC)
Severity, Prognosis, Stage
Complications
- Paraneoplastic Syndromes Seen in Patients with Lung Cancer

Therapy

Selection
- Small Cell Lung Cancer | Pretreatment Prognostic Score

Specialty

Hematology Oncology
Surgery, general
Pulmonology

Objective

options

ICD-10

C34.9 - Malignant neoplasm, bronchus or lung, unspecified

Molecular Testing of Lung Adenocarcinoma | EGFR Mutation Testing

Purpose: To identify a patient with a lung adenocarcinoma who may benefit from targeted therapy with specific tyrosine kinase inhibitors (TKI).